Anti-Xa levels 4 h after subcutaneous administration of 5,700 IU nadroparin strongly correlate with lean body weight in morbidly obese patients

Obesity Surgery

Volumn 22, Issue 5, 2012, Pages 791-796

  Diepstraten, Jeroen ^a   Hackeng, Christian M ^a   Van Kralingen, Simone ^a,b   Zapletal, Jiri ^a   Van Dongen, Eric P A ^a   Wiezer, René J ^a   Van Ramshorst, Bert ^a   Knibbe, Catherijne A J ^a,c  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Anti Xa; Lean body weight; Low molecular weight heparin; Morbid obesity; Nadroparin; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY SIZE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LEAN BODY WEIGHT; MALE; MORBID OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH BYPASS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 84862705345     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-012-0602-7     Document Type: Article

References (27)

1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-55.
2. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med. 2005;118(9):978-80. (Pubitemid 41297761)
3. Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ. 2002;325(7369):887-90. (Pubitemid 35215265)
4. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001;21(2):218-34. (Pubitemid 32119200)
5. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S-453S. (Pubitemid 351894916)
6. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):188S-203S. (Pubitemid 39297954)
7. Nutescu EA, Spinler SA, Wittkowsky A, et al. Low-molecularweight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43(6):1064-83.
8. Rondina MT, Wheeler M, Rodgers GM, et al.Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res. 2010;125(3):220-3.
9. Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis. 2008;4(5):625-31.
10. Singh K, Podolsky ER, Um S, et al. Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg. 2011 Apr 9. doi:10.1007/s11695-011-0397-y.
11. Kalfarentzos F, Stavropoulou F, Yarmenitis S, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg. 2001;11(6):670-6. (Pubitemid 34014518)
12. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051-65. (Pubitemid 41356391)
13. Rowland M, Tozer T. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2010.
14. Agnelli G, Iorio A, Renga C, et al. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation. 1995;92(10):2819-24.
15. Boneu B, Navarro C, Cambus JP, et al. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. Thromb Haemost. 1998;79(2):338-41. (Pubitemid 28065881)
16. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995;73(4):630-40.
17. Freedman MD, Leese P, Prasad R, et al. An evaluation of the biological response to fraxiparine, (a low molecular weight heparin) in the healthy individual. J Clin Pharmacol. 1990;30(8):720-7. (Pubitemid 20324622)
18. Harenberg J,Wurzner B, Zimmermann R, et al. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res. 1986;44(4):549-54. (Pubitemid 17200473)
19. Heizmann M, Baerlocher GM, Steinmann F, et al. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. Thromb Res. 2002;106(4-5):179-81. (Pubitemid 35248048)
20. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost. 2004;2(4):547-50. (Pubitemid 40185675)
21. Paige JT, Gouda BP, Gaitor-Stampley V, et al. No correlation between anti-factor Xa levels, low-molecular-weight heparin, and bleeding after gastric bypass. Surg Obes Relat Dis. 2007;3(4):469-75. (Pubitemid 47055401)
22. Bounameaux H, de Moerloose P. Is laboratory monitoring of lowmolecular- weight heparin therapy necessary? No. J Thromb Haemost. 2004;2(4):551-4. (Pubitemid 40185676)
23. Barras MA, Duffull SB, Atherton JJ, et al. Individualized compared with conventional dosing of enoxaparin. Clin Pharmacol Ther. 2008;83(6):882-8. (Pubitemid 351704919)
24. Lemmens HJ, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients. Obes Surg. 2006;16(6):773-6. (Pubitemid 43874836)
25. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. (Pubitemid 26099958)
26. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308-18.
27. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension. 1995;26(4):610-5.